Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M Texier
P012 Patients With Cancer and Preexisting Autoimmune and Inflammatory Diseases Treated by Anti-Programmed Death 1 (PD-1) Antibodies at Gustave Roussy Cancer Center
Related publications
Clinical Outcomes of Patients With Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated With Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
Oncologist
Cancer Research
Medicine
Oncology
Diverse Cutaneous Adverse Eruptions Caused by Anti-Programmed Cell Death-1 (PD-1) and Anti-Programmed Cell Death Ligand-1 (PD-L1) Immunotherapies: Clinical Features and Management
Therapeutic Advances in Medical Oncology
Oncology
2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer
Open Forum Infectious Diseases
Oncology
Neurology
Predictive Role of Computed Tomography Texture Analysis in Patients With Metastatic Urothelial Cancer Treated With Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors
European urology oncology
Oncology
Radiology
Urology
Nuclear Medicine
Imaging
Surgery
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies
JAMA Oncology
Cancer Research
Oncology
Clinical Significance of Soluble Programmed Cell Death-1 and Soluble Programmed Cell Death-Ligand 1 in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy
PLoS ONE
Multidisciplinary
The Prognostic Role of Immune Checkpoint Markers Programmed Cell Death Protein 1 (PD-1) and Programmed Death Ligand 1 (PD-L1) in a Large, Multicenter Prostate Cancer Cohort
Oncotarget
Oncology
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Frontiers in Oncology
Cancer Research
Oncology
Cancer Immunotherapy With Immunomodulatory Anti-Cd137 and Anti-Pd-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
Cancer Discovery
Oncology
